MX2019014430A - Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. - Google Patents
Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.Info
- Publication number
- MX2019014430A MX2019014430A MX2019014430A MX2019014430A MX2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A MX 2019014430 A MX2019014430 A MX 2019014430A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- bet
- methods
- fagales
- allergens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513872P | 2017-06-01 | 2017-06-01 | |
| US201762571696P | 2017-10-12 | 2017-10-12 | |
| US201862662165P | 2018-04-24 | 2018-04-24 | |
| PCT/US2018/035366 WO2018222854A1 (en) | 2017-06-01 | 2018-05-31 | Human antibodies to bet v 1 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014430A true MX2019014430A (es) | 2020-07-14 |
Family
ID=62705709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014430A MX2019014430A (es) | 2017-06-01 | 2018-05-31 | Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. |
| MX2023000390A MX2023000390A (es) | 2017-06-01 | 2019-11-29 | Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000390A MX2023000390A (es) | 2017-06-01 | 2019-11-29 | Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10793624B2 (https=) |
| EP (1) | EP3630814A1 (https=) |
| JP (3) | JP6963036B2 (https=) |
| KR (3) | KR102329175B1 (https=) |
| CN (1) | CN110997713B (https=) |
| AU (2) | AU2018275657B2 (https=) |
| BR (1) | BR112019025150B1 (https=) |
| CA (1) | CA3063588A1 (https=) |
| CL (3) | CL2019003508A1 (https=) |
| CO (1) | CO2019013196A2 (https=) |
| IL (2) | IL270894B2 (https=) |
| MX (2) | MX2019014430A (https=) |
| MY (1) | MY198270A (https=) |
| NZ (1) | NZ759513A (https=) |
| PH (1) | PH12019550238A1 (https=) |
| WO (1) | WO2018222854A1 (https=) |
| ZA (1) | ZA201907513B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| IL308643B2 (en) | 2017-05-05 | 2025-02-01 | Regeneron Pharma | Auto-injector |
| IL270894B2 (en) * | 2017-06-01 | 2023-04-01 | Regeneron Pharma | Human antibodies to bet v 1 and methods of using them |
| AU2021300129A1 (en) | 2020-07-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-Bet v 1 antibodies |
| CN113041271B (zh) * | 2021-04-14 | 2022-12-27 | 浙江养生堂天然药物研究所有限公司 | 具有预防和抗过敏功效的组合物 |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| US20230174632A1 (en) * | 2021-12-08 | 2023-06-08 | IgGenix, Inc. | Combinations for allergy therapy |
| EP4688165A1 (en) | 2023-03-31 | 2026-02-11 | ALK-Abelló A/S | Allergen binding antibodies suitable for treating tree pollen allergies |
| WO2024251358A1 (en) * | 2023-06-07 | 2024-12-12 | Mabylon Ag | Anti-allergen antibodies and uses thereof |
| CN121548440A (zh) | 2023-06-16 | 2026-02-17 | 里珍纳龙药品有限公司 | 医疗装置包装及相关方法 |
| US20250011403A1 (en) * | 2023-07-03 | 2025-01-09 | Medicovestor, Inc. | Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| WO2025075970A1 (en) | 2023-10-02 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
| US12364777B2 (en) | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| WO2025117894A2 (en) * | 2023-11-29 | 2025-06-05 | Medicovestor, Inc. | Dimeric immunoconjugates for use in treating cancers and methods of use |
| US12116410B1 (en) | 2023-12-26 | 2024-10-15 | Medicovestor, Inc. | Methods of manufacturing dimeric antibodies |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| US20250263471A1 (en) | 2024-01-30 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5411594A (en) | 1992-10-27 | 1994-05-24 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order |
| WO1994014475A1 (en) | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| EP0619323A1 (en) * | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| ITMI20052517A1 (it) * | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AT503297B1 (de) * | 2006-05-18 | 2007-09-15 | Biomay Ag | Allergen-spezifische antikörper |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US10935554B2 (en) * | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| IL270894B2 (en) | 2017-06-01 | 2023-04-01 | Regeneron Pharma | Human antibodies to bet v 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| AU2021300129A1 (en) * | 2020-07-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-Bet v 1 antibodies |
-
2018
- 2018-05-31 IL IL270894A patent/IL270894B2/en unknown
- 2018-05-31 MY MYPI2019006625A patent/MY198270A/en unknown
- 2018-05-31 KR KR1020197036599A patent/KR102329175B1/ko active Active
- 2018-05-31 CN CN201880049949.7A patent/CN110997713B/zh active Active
- 2018-05-31 AU AU2018275657A patent/AU2018275657B2/en active Active
- 2018-05-31 BR BR112019025150-2A patent/BR112019025150B1/pt active IP Right Grant
- 2018-05-31 NZ NZ759513A patent/NZ759513A/en unknown
- 2018-05-31 WO PCT/US2018/035366 patent/WO2018222854A1/en not_active Ceased
- 2018-05-31 KR KR1020247018848A patent/KR102878718B1/ko active Active
- 2018-05-31 EP EP18733431.3A patent/EP3630814A1/en active Pending
- 2018-05-31 JP JP2019565912A patent/JP6963036B2/ja active Active
- 2018-05-31 MX MX2019014430A patent/MX2019014430A/es unknown
- 2018-05-31 KR KR1020217037411A patent/KR102674000B1/ko active Active
- 2018-05-31 US US15/994,294 patent/US10793624B2/en active Active
- 2018-05-31 CA CA3063588A patent/CA3063588A1/en active Pending
- 2018-05-31 IL IL298034A patent/IL298034B2/en unknown
-
2019
- 2019-11-13 ZA ZA2019/07513A patent/ZA201907513B/en unknown
- 2019-11-14 PH PH12019550238A patent/PH12019550238A1/en unknown
- 2019-11-26 CO CONC2019/0013196A patent/CO2019013196A2/es unknown
- 2019-11-29 MX MX2023000390A patent/MX2023000390A/es unknown
- 2019-11-29 CL CL2019003508A patent/CL2019003508A1/es unknown
-
2020
- 2020-08-28 US US17/006,599 patent/US11767358B2/en active Active
-
2021
- 2021-04-27 JP JP2021074862A patent/JP7162097B2/ja active Active
- 2021-10-29 CL CL2021002850A patent/CL2021002850A1/es unknown
- 2021-10-29 CL CL2021002851A patent/CL2021002851A1/es unknown
-
2022
- 2022-01-17 AU AU2022200272A patent/AU2022200272B2/en active Active
- 2022-09-15 JP JP2022146982A patent/JP7458453B2/ja active Active
-
2023
- 2023-08-09 US US18/232,238 patent/US20240083986A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000390A (es) | Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos. | |
| ZA202202846B (en) | Human antibodies to fel d1 and methods of use thereof | |
| WO2016142783A3 (en) | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof | |
| MY171180A (en) | Anti-hla-b*27 antibodies and uses thereof | |
| GEP20237480B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| MY146664A (en) | Antibodies against human il-22 and uses therefor | |
| JO3744B1 (ar) | مواد ربط لـpd1 و/ أو lag3 | |
| EP2447280A3 (en) | VEGF analogs and methods of use | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| HK1250238A1 (zh) | 抗angptl8抗体及其用途 | |
| CL2013003640A1 (es) | Proteina de union a il-17, construccion que comprende dicha proteina, un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de dicha proteina; acido nucleico que la codifica; vector; celula huesped, metodo de produccion; composicion que la comprende; y su uso para reducir la actividad de la il-17 en una patologia en la cual il-17 es perjudicial (div.sol.2129-11). | |
| MX392069B (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| MX2016005762A (es) | Region variable de anticuerpo modificada que contiene molecula de union al antigeno. | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| WO2014026804A3 (de) | Mittel und verfahren zur temporären verformung keratinhaltiger fasern | |
| DE602006011859D1 (de) | T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon | |
| WO2014165028A8 (en) | Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases | |
| EA201992651A1 (ru) | АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| WO2015061610A3 (en) | Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations | |
| WO2015077434A3 (en) | Pan pollen immunogens and methods and uses thereof for immune response modulation | |
| TH1801000535A (th) | โครงสร้างแอนติบอดีที่มีความจำเพาะแบบคู่ที่จับdll3และcd3 | |
| TH97938A (th) | แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น | |
| TH1901000781A (th) | สบู่ซึ่งมีส่วนประกอบของน้ำมันกฤษณาและทองคำ | |
| KR20180070830A (ko) | 주사위고정 과 니들길이 조절캡 |